Factor VII Paired Antibody Set
Affinity’s Factor VII Paired Antibody Set consists of matched capture and detecting antibodies that have been titrated and optimized for use in sandwich style ELISA assays. The product as provided contains sufficient capture and detecting antibodies for five full 96-well microplates and contains a detailed protocol sheet containing directions for use, recipes for solutions and sources for additional materials required. This Factor VII Paired Antibody Set is intended to facilitate the end user in establishing an “in-house” immunoassay for research purposes only and must not be used for diagnostic applications. Assay validation is the responsibility of the end user.
Product Code: FVII-EIA
- Capture Antibody (FVII-EIA-C): One yellow-capped vial containing 0.5 ml of purified monoclonal anti-Factor VII antibody for coating plates.
- Detecting Antibody (FVII-EIA-D): One red-capped tube containing 0.5 ml of peroxidase conjugated affinity-purified polyclonal anti-Factor VII antibody for detection of captured Factor VII.
Species Cross Reactivity: View Chart
Product Datasheet: Factor VII (F7 FVII) Antigen Matched Pair Antibody Set for ELISA - FVII-EIA
Description of Factor VII
Factor VII (FVII, also known as Stable Factor and Proconvertin) is a vitamin K-dependent glycoprotein produced in the liver. Plasma concentration of FVII is normally ~0.5 μg/ml (10 nM) in plasma. A deficiency of FVII is associated with bleeding in a clinical pattern similar to haemophilia, but is inherited as an autosomal recessive trait. The deficiency can be characterized by a quantitative (low activity and low antigen) or a qualitative (low activity and normal antigen) defect in FVII function. In its zymogen form FVII is a single chain molecule of ~50 kDa. It contains two EGF-like domains and an amino-terminal domain containing 10 γ-carboxyglutamic acid (Gla) residues. These Gla residues allow FVII to bind divalent metal ions and participate in calcium-dependent binding interactions. FVII and activated FVII (FVIIa) bind to tissue factor exposed at the site of vascular injury. FIXa, FXa or FVIIa rapidly activate tissue factor-bound FVII to FVIIa in the presence of calcium and phospholipid. Thrombin and FXIIa are able to activate FVII in the fluid phase in the absence of cofactors. The activation of the single chain zymogen FVII occurs by proteolysis after residue Arg152, resulting in a two-chain active serine protease consisting of a 30 kDa heavy chain and a 18 kDa light chain. In complex with tissue factor, phospholipid and calcium, FVIIa is able to activate F.X and F.IX. Free FVIIa in plasma is remarkably stable, but the activity of FVIIa/TF complex is regulated by Tissue Factor Pathway Inhibitor (TFPI) in the presence of F.Xa, and also by Antithrombin (ATIII) in the presence of heparin1-3.
References and Reviews
- Rao LVM, Bajaj SP, Rapaport SI; Activation of Human Factor VII During Clotting in Vitro; Blood 65, pp 218-226, 1985.
- Lawson, JH, Butenas S, Ribarik N, Mann KG; Complex-dependent Inhibition of Factor VIIa by Antithrombin III and Heparin; JBC 268 pp 767-770, 1993.
- Nemerson Y, in Hemostasis and Thrombosis, 3rd Edition, eds. RW Colman, J Hirsh, VJ Marder and EW Salzman, pp. 81-93, J.B. Lippincott Co., Philadelphia PA, USA, 1994.